Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis

Recruiting

Phase 2

ARQ-151Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis

Sponsor:

Arcutis Biotherapeutics, Inc.

Code:

NCT06998056

Conditions

Atopic Dermatitis (Eczema)

Eligibility Criteria

Sex: All

Age: 0 - 2

Healthy Volunteers: Not accepted

Interventions

ARQ-151 cream 0.05%

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-10. This information was provided to ClinicalTrials.gov by Arcutis Biotherapeutics, Inc. on 2025-06-17.